U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Gastroesophageal Junction Adenocarcinoma

MedGen UID:
1696814
•Concept ID:
C5206632
•
Neoplastic Process

Definition

Gastroesophageal junction adenocarcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Gastroesophageal Junction Adenocarcinoma

Professional guidelines

PubMed

Endoscopic anti-reflux mucosectomy (ARMS) and endoscopic anti-reflux ablation (ARMA) as a potential treatment for gastroesophageal reflux - preliminary report.
Klimczak T, Strzelczyk J
Pol Przegl Chir 2023 Oct 12;96(0):1-5. doi: 10.5604/01.3001.0053.9251. PMID: 38348994
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E
Oncologist 2021 Oct;26(10):e1704-e1729. Epub 2021 Sep 3 doi: 10.1002/onco.13907. PMID: 34288262Free PMC Article
Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol 2017 Nov;33(6):473-476. doi: 10.1097/MOG.0000000000000395. PMID: 28877045

Recent clinical studies

Etiology

Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H
J Clin Oncol 2016 May 1;34(13):1448-54. Epub 2016 Feb 16 doi: 10.1200/JCO.2015.63.5995. PMID: 26884585
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data.
Janowitz T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, Dunn J, Park SH, Ford H
Br J Cancer 2016 Feb 16;114(4):381-7. doi: 10.1038/bjc.2015.452. PMID: 26882063Free PMC Article

Diagnosis

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J
Br J Cancer 2024 Feb;130(3):476-482. Epub 2023 Dec 22 doi: 10.1038/s41416-023-02534-1. PMID: 38135713Free PMC Article
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Zhang C, Yu GM, Zhang M, Liu D
Medicine (Baltimore) 2020 Jan;99(1):e18691. doi: 10.1097/MD.0000000000018691. PMID: 31895837Free PMC Article
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL
Oncologist 2018 Oct;23(10):1171-1177. Epub 2018 Apr 27 doi: 10.1634/theoncologist.2018-0034. PMID: 29703766Free PMC Article
Electrostimulation for intractable delayed emptying of intrathoracic stomach after esophagectomy.
Salameh JR, Aru GM, Bolton W, Abell TL
Ann Thorac Surg 2008 Apr;85(4):1417-9. doi: 10.1016/j.athoracsur.2007.09.044. PMID: 18355538

Therapy

Immunotherapy in esophagogastric cancer.
Ilson DH
Clin Adv Hematol Oncol 2021 Oct;19(10):639-647. PMID: 34637430Free PMC Article
Camrelizumab: First Global Approval.
Markham A, Keam SJ
Drugs 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0. PMID: 31313098
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M
Ann Oncol 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199. PMID: 31240302Free PMC Article
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Prognosis

Detection of a Novel MSI2-C17orf64 Transcript in a Patient with Aggressive Adenocarcinoma of the Gastroesophageal Junction: A Case Report.
Ferrari A, Fiocca R, Bonora E, Domizio C, Fonzi E, Angeli D, Domenico Raulli G, Mattioli S, Martinelli G, Molinari C
Genes (Basel) 2023 Apr 15;14(4) doi: 10.3390/genes14040918. PMID: 37107676Free PMC Article
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY
Clin Cancer Res 2020 Feb 15;26(4):846-854. Epub 2019 Nov 1 doi: 10.1158/1078-0432.CCR-19-2443. PMID: 31676670Free PMC Article
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL
Oncologist 2018 Oct;23(10):1171-1177. Epub 2018 Apr 27 doi: 10.1634/theoncologist.2018-0034. PMID: 29703766Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data.
Janowitz T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, Dunn J, Park SH, Ford H
Br J Cancer 2016 Feb 16;114(4):381-7. doi: 10.1038/bjc.2015.452. PMID: 26882063Free PMC Article

Clinical prediction guides

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.
Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Saeed A, Ripp J, Collins Z, Mulvaney K, Shugrue M, Firth-Braun J, Godwin AK, Madan R, Phadnis M, Sun W
Cell Rep Med 2023 Feb 21;4(2):100916. Epub 2023 Jan 25 doi: 10.1016/j.xcrm.2023.100916. PMID: 36702123Free PMC Article
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL
Oncologist 2018 Oct;23(10):1171-1177. Epub 2018 Apr 27 doi: 10.1634/theoncologist.2018-0034. PMID: 29703766Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data.
Janowitz T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, Dunn J, Park SH, Ford H
Br J Cancer 2016 Feb 16;114(4):381-7. doi: 10.1038/bjc.2015.452. PMID: 26882063Free PMC Article

Recent systematic reviews

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E
Oncologist 2021 Oct;26(10):e1704-e1729. Epub 2021 Sep 3 doi: 10.1002/onco.13907. PMID: 34288262Free PMC Article
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A, Park R, Sun W
J Hematol Oncol 2021 Jan 12;14(1):13. doi: 10.1186/s13045-021-01034-0. PMID: 33436042Free PMC Article
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...